Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction : Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
The drug will be given over a maximum 14 weeks with up to four weeks titrating up, eight weeks maintaining highest tolerable dose, and up to two weeks tapering down. Change in olfactory function from baseline to completion of 8-week fixed-dose period will be compared between the two study groups. Follow-up assessments will be conducted for both groups 4 weeks after completion of taper down..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 05. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: January 11, 2022, Last downloaded: ClinicalTrials.gov processed this data on April 10, 2024, Last updated: April 10, 2024 |
|---|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG008112703 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG008112703 | ||
| 003 | DE-627 | ||
| 005 | 20240410010604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220112s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG008112703 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05184192 | ||
| 035 | |a (UBBS_Klinische_Studien)202110011 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction |b Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: January 11, 2022, Last downloaded: ClinicalTrials.gov processed this data on April 10, 2024, Last updated: April 10, 2024 | ||
| 520 | |a The drug will be given over a maximum 14 weeks with up to four weeks titrating up, eight weeks maintaining highest tolerable dose, and up to two weeks tapering down. Change in olfactory function from baseline to completion of 8-week fixed-dose period will be compared between the two study groups. Follow-up assessments will be conducted for both groups 4 weeks after completion of taper down. | ||
| 650 | 2 | |a COVID-19 | |
| 650 | 2 | |a Anosmia | |
| 650 | 2 | |a Olfaction Disorders | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 05. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:04 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05184192 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 04 | ||